Track market-moving stories before they get noisy

The South Korean company is aiming to raise tens of billions of dollars as it battles to meet soaring demand for memory chips.

Micron stock NASDAQ:MU reports fiscal third-quarter earnings after the US market close on Wednesday, and the options market has already marked the event as a potential shock.

The stock has been one of the biggest AI winners of the year, with gains of more than 800% over the past 12 months and a market value that has pushed above $1 trillion.

That makes tonight’s print a test of whether the AI hardware boom can keep outrunning even the most aggressive expectations.

The options chain was already telling that story before a single number dropped.

Saxo Bank said Micron’s near-term options were pricing in an implied move of about 11% in either direction after earnings.

That does not mean traders are betting the stock will rise 11%. It means the market is attaching a high price to uncertainty.

Based on a reference stock price of $1,172.30, Saxo said the options market was implying a post-earnings range of roughly $1,066 to $1,331.

That is a very wide earnings window, even for a stock that has become central to the AI trade.

The reason is volatility, as Saxo pegged front-week implied volatility at about 155%, compared with roughly 109% for July options.

In plain English, the market is charging a huge premium for options that cover the earnings event.

That creates a risk known as “IV crush”. Once the results are out, that event premium can disappear quickly.

A trader can get the direction right and still lose money if Micron’s actual move is smaller than the move already priced into the option.

For ordinary investors, the message is simpler: the market expects fireworks, but it is not saying which way the blast goes.

The reason traders are willing to price such a large move is that Micron is no longer being treated like a normal memory-cycle stock.

TD Cowen analyst Krish Sankar recently lifted his price target on Micron to $1,500 from $660. The core of his argument was blunt: the role of memory in AI is “structural rather than cyclical”.

That phrase matters as memory stocks have historically moved through boom-and-bust cycles. Prices rise, manufacturers add supply, margins peak, and the cycle eventually rolls over.

Wall Street is now asking whether AI has changed that pattern.

Bank of America’s Vivek Arya also raised his Micron target to $1,500 from $950. The timing was notable because the upgrade came as the stock was selling off.

That made the call less like a momentum chase and more like a statement of conviction.

Other target increases have followed the same direction.

TheStreet cited UBS at $1,625, Needham at $1,550, and several other firms clustered well above the stock’s recent trading range.

The fundamental story is high-bandwidth memory, or HBM. These chips sit alongside advanced AI accelerators and are essential for training and running large models.

Supply remains tight, pricing power has extended, and analysts are increasingly treating Micron as a core AI infrastructure beneficiary rather than a commodity memory maker.

Micron’s own guidance has raised the bar. The company guided for fiscal Q3 revenue of $33.5 billion at the midpoint and gross margin of about 81%.

For a memory chipmaker, that margin level would be extraordinary, but it also leaves little room for disappointment.

AI stocks mount a comeback after getting hammered the previous session on worries about leverage in the market and higher rates.

Intuitive Surgical has become a more attractive opportunity after a 28% stock decline, prompting an upgrade from Hold to Buy. ISRG operates in a high-growth surgical robotics market, which could nearly triple by 2033, supporting long-term bullishness. Despite a premium valuation, ISRG's consistent top and bottom-line growth and management execution justify its price.

Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) is positioned for multi-decade compounding because it sits at the center of an aging-world healthcare megatrend with a razor-and-blade business model that compounds quietly whether the broader market is euphoric or fearful.

The case for permanence rests on three pillars, and none of them depend on a single quarter, a single product cycle, or a single economic regime.

Pillar 1: Durability That Strengthens With Every Install Wall Street still occasionally treats Intuitive like a cyclical capital goods manufacturer fixated on how many multi-million-dollar systems hospitals buy each quarter. The bigger picture is that the more systems Intuitive installs globally, the more its revenue mix structurally shifts toward proprietary instruments, accessories, and service contracts required for every procedure performed. The installed base now stands at 11,395 da Vinci systems and 1,041 Ion systems, with recurring revenue of $2.4 billion representing 86% of total revenue in Q1 2026. Intuitive captures roughly 80% of the robotic surgery market, and surgeon training, hospital capex sunk into existing systems, and consumable lock-in make that moat widen with time rather than erode.

Pillar 2: Compounding Through Buybacks and a Fortress Balance Sheet There is no dividend here. Capital returns flow through buybacks and reinvestment, and the math is unambiguous. The company repurchased 2.3 million shares for $1.1 billion in Q1 2026 after buying back 4.0 million shares for $1.92 billion in Q3 2025. The balance sheet carries $7.98 billion in cash against just $2.51 billion in total liabilities. Earnings are compounding visibly: $2.50 in Q1 2026 versus $1.50 in Q1 2024, with 22 of the last 24 quarters beating consensus.

Healthcare is also pulling its weight as a sector. U.S. personal healthcare spending reached $3,700.1 billion in April 2026, up from $3,494.0 billion a year earlier. Demographics do the rest of the work.

Pillar 3: Why It Survives Cycles Recessions hit capital goods makers because customers postpone big-ticket purchases. Intuitive is insulated because procedures continue even when system orders slow, and consumables ride those procedures. Worldwide da Vinci procedures grew 16% and Ion procedures grew 39% in Q1 2026, and Instruments & Accessories revenue of $1.69 billion grew 23%. That recurring stream is what carries the business through downturns.

Where It Underperforms, and Why It Doesn’t Matter The realistic underperformance scenario is a hospital capex freeze combined with tariff escalation. Guidance already bakes in roughly a 1.0% tariff headwind tied to manufacturing in Mexico and Germany and materials from China. Shares reflect this concern, down 28.99% year to date and 21.47% over the past year. System placements can slow in a recession. Procedures, consumables, and the installed base keep compounding regardless, which is exactly why the forever thesis holds. The 10-year return of 464.03% was built through several of these scares.

Forward earnings sit at 40x, which is the price of admission for owning the dominant platform in a structurally growing field. The setup favors long-term ownership over short-term trading.

Intuitive Surgical, Inc. (ISRG - Free Report) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Over the past month, shares of this company have returned -8%, compared to the Zacks S&P 500 composite's +0.1% change. During this period, the Zacks Medical - Instruments industry, which Intuitive Surgical falls in, has lost 1.2%. The key question now is: What could be the stock's future direction?

Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.

Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.

We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For the current quarter, Intuitive Surgical is expected to post earnings of $2.48 per share, indicating a change of +13.2% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

The consensus earnings estimate of $10.41 for the current fiscal year indicates a year-over-year change of +16.6%. This estimate has remained unchanged over the last 30 days.

For the next fiscal year, the consensus earnings estimate of $11.7 indicates a change of +12.4% from what Intuitive Surgical is expected to report a year ago. Over the past month, the estimate has changed -0.1%.

Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Intuitive Surgical is rated Zacks Rank #2 (Buy).

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Revenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Intuitive Surgical, the consensus sales estimate of $2.81 billion for the current quarter points to a year-over-year change of +15%. The $11.72 billion and $13.18 billion estimates for the current and next fiscal years indicate changes of +16.5% and +12.4%, respectively.

Last Reported Results and Surprise HistoryIntuitive Surgical reported revenues of $2.77 billion in the last reported quarter, representing a year-over-year change of +23%. EPS of $2.5 for the same period compares with $1.81 a year ago.

Compared to the Zacks Consensus Estimate of $2.61 billion, the reported revenues represent a surprise of +6.24%. The EPS surprise was +20.19%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.

The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an A is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Intuitive Surgical is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Intuitive Surgical. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term.

George Hill, Anguilla, 23 June 2026 -- New Anglia University highlights several important trends that continue to shape the future of Graduate Medical Education (GME) in the United States as healthcare systems adapt to evolving patient needs, workforce demands, technological advancements, and changing models of care delivery.

Graduate Medical Education serves as the bridge between medical school and independent clinical practice, providing physicians with the specialized training, supervision, and practical experience required to deliver safe and effective patient care. As healthcare continues to evolve, residency training programs are also adapting to ensure future physicians are prepared for increasingly complex clinical environments.

Graduate Medical Education Continues to Expand

In recent years, the United States has seen continued growth in residency training opportunities. According to data from the National Resident Matching Program (NRMP), the 2025 Main Residency Match offered more than 43,000 residency positions, representing continued expansion in Graduate Medical Education capacity and the largest Match in the organization's history. The number of residency positions has increased steadily over the past decade as healthcare organizations seek to address physician workforce needs across a variety of specialties and geographic regions.

The expansion of Graduate Medical Education reflects broader efforts to strengthen healthcare capacity while ensuring that future physicians receive the clinical experience necessary to meet growing patient demand. As populations age and healthcare needs become increasingly complex, residency programs play a critical role in preparing physicians for the realities of modern clinical practice.

At the same time, policymakers, healthcare leaders, and educational institutions continue to examine how residency training can evolve to better support workforce planning, improve healthcare access, and address physician shortages in underserved communities.

A Growing Emphasis on Clinical Readiness

One of the most significant trends in Graduate Medical Education is the increasing emphasis on clinical readiness. Residency programs are placing greater focus on ensuring that incoming physicians possess not only strong academic foundations but also the practical skills, professionalism, communication abilities, and clinical judgment required to succeed in patient care environments.

Healthcare systems today require physicians who can work effectively within multidisciplinary teams, adapt to rapidly changing clinical situations, and navigate increasingly complex healthcare delivery models. As a result, medical educators are placing greater importance on experiential learning, clinical exposure, simulation-based education, and competency development throughout the medical education continuum.

The transition from medical school to residency remains a critical stage of physician training and continues to be a major focus of Graduate Medical Education.

Preparing Students for Modern Residency Pathways

As expectations within Graduate Medical Education continue to evolve, medical schools are increasingly focused on ensuring that students are prepared not only to enter residency training but also to thrive within increasingly demanding clinical environments. In addition to strong academic foundations, clinical exposure and familiarity with healthcare delivery systems have become important components of physician development.

New Anglia University's Doctor of Medicine (MD) programme has been designed to provide students with an integrated medical education that combines foundational medical sciences with extensive clinical training opportunities. Through the University's network of affiliated teaching hospitals and healthcare partners, students have the opportunity to undertake clinical rotations in the United States, gaining exposure to patient care, healthcare delivery models, multidisciplinary clinical teams, and the professional expectations commonly encountered within residency training environments.

For students considering future residency opportunities, early exposure to healthcare environments can help develop professional confidence, patient communication abilities, and an understanding of multidisciplinary care delivery. As Graduate Medical Education increasingly emphasises clinical readiness, these experiences can play an important role in supporting the transition from medical school to residency training, while helping students better understand postgraduate training pathways and professional expectations within the U.S. healthcare system.

Technology Is Transforming Medical Training

Advances in healthcare technology are also influencing the future of Graduate Medical Education. Simulation laboratories, digital learning platforms, telemedicine, artificial intelligence, and data-driven healthcare systems are increasingly being incorporated into physician training.

While technology cannot replace direct patient interaction, it is creating new opportunities for medical trainees to develop clinical skills, practice decision-making, and gain exposure to complex scenarios in controlled learning environments.

As healthcare organizations continue to adopt new technologies, residency programs are increasingly focused on preparing physicians to work effectively in technology-enabled clinical settings while maintaining the human-centered approach that remains central to patient care.

Interprofessional Collaboration Is Becoming Increasingly Important

Modern healthcare delivery relies on collaboration among physicians, nurses, pharmacists, therapists, administrators, and other healthcare professionals. As a result, Graduate Medical Education is placing greater emphasis on interprofessional learning and team-based care.

Training environments increasingly encourage physicians to develop communication, leadership, and collaborative skills alongside their clinical competencies. These experiences help prepare residents for the realities of contemporary healthcare systems, where effective teamwork is often essential to achieving positive patient outcomes.

The growing focus on interprofessional education reflects a broader recognition that high-quality healthcare depends not only on individual expertise but also on the ability of healthcare professionals to work together effectively.

Competency-Based Medical Education Is Gaining Momentum

Another important trend shaping the future of Graduate Medical Education is the growing emphasis on competency-based physician training. Traditionally, medical education has relied heavily on time-based progression, with physicians advancing through residency according to predetermined training schedules. Increasingly, however, educators are focusing on the demonstration of specific competencies and measurable outcomes.

Competency-based approaches place greater emphasis on clinical performance, patient safety, communication skills, professionalism, procedural competence, and the ability to deliver high-quality patient care. Rather than simply measuring time spent in training, programs are seeking to ensure that residents demonstrate the knowledge, skills, and behaviours required for independent practice.

This evolution reflects broader efforts to enhance educational quality while ensuring that residency graduates are fully prepared to meet the demands of modern healthcare systems. As Graduate Medical Education continues to evolve, competency-based assessment is expected to play an increasingly important role in physician development.

International Medical Graduates Continue to Play a Vital Role

Graduate Medical Education in the United States is also shaped by the significant contribution of International Medical Graduates (IMGs). According to data from the Educational Commission for Foreign Medical Graduates (ECFMG), the American Medical Association (AMA), and other healthcare workforce analyses, approximately one-quarter of practicing physicians in the United States graduated from medical schools outside the country.

Many residency programs rely on International Medical Graduates to help meet workforce needs, particularly in primary care, internal medicine, family medicine, and underserved communities. As healthcare demand continues to grow, the contribution of IMGs remains an important component of the broader physician workforce.

The continued integration of qualified International Medical Graduates into U.S. residency training highlights the increasingly global nature of medical education and healthcare delivery. As physician mobility increases and healthcare systems become more interconnected, Graduate Medical Education is expected to remain an important bridge between international medical training and clinical practice in the United States.

Preparing Physicians for a Changing Healthcare Landscape

The healthcare environment facing future physicians is markedly different from that of previous generations. Demographic shifts, evolving patient expectations, healthcare technology, population health initiatives, and changing workforce needs continue to influence how care is delivered throughout the United States.

The need for a well-trained physician workforce remains particularly significant. The Association of American Medical Colleges (AAMC) has projected that the United States could face a shortage of between approximately 13,500 and 86,000 physicians by 2036, driven by population growth, demographic changes, and increasing demand for healthcare services. These projections continue to shape discussions surrounding physician training capacity, residency funding, and long-term workforce planning.

Graduate Medical Education must therefore remain adaptable, ensuring that physicians are prepared to meet both current and future healthcare challenges. Residency programs increasingly seek to balance traditional clinical training with broader competencies that support leadership, quality improvement, patient safety, healthcare systems understanding, and lifelong learning.

As healthcare continues to evolve, the ability to adapt to new clinical environments and emerging challenges will remain an essential characteristic of successful physicians.

Looking Ahead

As the United States continues to address future healthcare workforce needs, Graduate Medical Education is expected to evolve in response to changing healthcare priorities, technological innovation, workforce demands, and patient expectations. Programs will likely place increasing emphasis on clinical competence, adaptability, interdisciplinary collaboration, digital health literacy, and lifelong learning as physicians prepare for a rapidly changing healthcare environment.

For medical students and future physicians, understanding these trends provides valuable insight into how residency training is changing and what skills will be most important in the years ahead. While the foundations of medicine remain constant, the methods used to train and support future physicians continue to evolve alongside the healthcare systems they will ultimately serve.

Contact details: [email protected] Tel: +1 264 498 3768/+44(0) 204 553 3768

GRAPEVINE, Texas--(BUSINESS WIRE)--GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today announced that its Board of Directors (the "Board") has granted the request of Ryan Cohen, Chairman and CEO, to amend the Company's proxy statement to remove the proposed CEO Performance Award. When the Board approved the CEO Performance Award in January 2026, the Company had not yet decided to pursue the acquisition of eBay, Inc. ("eBay").

Mr. Cohen stated that he wants leadership fully focused on GameStop's operating performance and its proposed eBay acquisition.

Additional details can be found in a supplement to the Company's proxy statement filed with the Securities and Exchange Commission. GameStop will release additional materials regarding its proposed acquisition of eBay this week, including a detailed presentation of the strategic rationale and operational plan for the combined company.

No Offer or Solicitation

This communication relates to a business combination involving GameStop and eBay that has been proposed by GameStop (the “Proposed Transaction”). This communication is for informational purposes only and is neither an offer to sell or purchase, nor the solicitation of an offer to buy or sell, any securities (or the solicitation of any proxy or vote with respect to any matter), nor shall there be any sale or purchase, issuance or other transfer of securities (or the solicitation of any proxy or other vote) with respect to the Proposed Transaction or otherwise in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Certain Information Regarding Participants

GameStop and its directors and certain of its executive officers may be considered participants in the solicitation of proxies in connection with the Proposed Transaction, should the Proposed Transaction and any such solicitation occur. Information about the directors and executive officers of GameStop is set forth in GameStop’s definitive proxy statement for the 2026 Annual Meeting of Stockholders to be held July 7, 2026 at 10:00 a.m. CDT, which was filed with the SEC on May 22, 2026 (as supplemented from time to time, the “2026 Proxy Statement”), which is available here, including under the headings “Proposal 1: Election of Directors”, “Director Nomination Process”, “The Director Nominees”, “Director Nominee Qualifications and Experience”, “Biographies of Director Nominees”, “The Board of Directors”, “Corporate Governance”, “Director Compensation”, “Executive Officers”, “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters”, “Compensation Committee Interlocks and Insider Participation”, “Proposal No. 2: Advisory Vote on Executive Compensation”, “Compensation Discussion and Analysis”, “Offer Letters and Severance/Change in Control Benefits”, “Compensation Committee Report on Executive Compensation”, “Executive Compensation Tables”, “CEO Pay Ratio”, “Pay Versus Performance”, “Equity Grant Practices”, “Securities Authorized for Issuance Under Equity Compensation Plans”, “Audit Committee Matters”, “Certain Relationships and Related Transactions”, “Proposal 4: Approval of CEO Performance Award”, “Summary of the Proposed CEO Performance Award”, “Reasons for Approval of the CEO Performance Award”, “Market Capitalization Hurdles with Cumulative Performance EBITDA Hurdles Create Real Value for Stockholders”, “Background of the CEO Performance Award”, “Key Terms of the Proposed CEO Performance Award”, “Other Details Regarding the Proposed CEO Performance Award”, “The Compensation Committee’s Assessment of the CEO Performance Award”, “Practical Implications of the CEO Performance Award” and “Appendix A: CEO Performance Award Agreement”. To the extent holdings of such persons in the Company’s securities have changed since the amounts described in the 2026 Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Additional information can also be found in the Company’s Annual Report on Form 10-K for the fiscal year ended January 31, 2026, filed with the SEC on March 24, 2026, which is available here.

As of the date hereof, GameStop directly beneficially owns 4,343,725 shares of common stock of eBay, par value $0.001 per share (the “Common Stock”), and has further entered into the long-side of a series of American-style put/call option transactions (the “Put/Call Pairs”), expiring February 23, 2028, with an unaffiliated financial institution counterparty that provide economic exposure to a further 39,046,658 shares of Common Stock. The Put/Call Pairs were only settleable in cash until such time as GameStop provided the unaffiliated financial institution counterparty with reasonable evidence that all applicable filings had been made and any applicable waiting periods had expired or approvals had been received, as applicable, under the Hart Scott Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act Condition”). On June 3, 2026, the HSR Act Condition was satisfied, and as a result, GameStop (in the case of the call portion of the Put/Call Pairs) and the unaffiliated financial institution counterparty (in the case of the put portion of the Put/Call Pairs) electing to settle the Put/Call Pairs now have the option, but not the obligation, to elect for physical settlement of the shares of Common Stock underlying such Put/Call Pairs in lieu of cash settlement. GameStop does not have voting power or dispositive power with respect to the shares of Common Stock underlying such Put/Call Pairs unless and until such Put/Call Pairs are physically settled for Common Stock. On May 3, 2026, GameStop delivered to the board of directors of eBay a non-binding proposal to acquire all of the outstanding Common Stock that it does not already own at a price of $125 per share of Common Stock, to be paid in a combination of cash and GameStop common stock. As a result of the foregoing, GameStop may be deemed to have direct or indirect interests with respect to eBay that are in addition to, or different from, those of other eBay shareholders.

Further information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in any proxy statement/prospectus and/or other relevant materials to be filed with the SEC in connection with the Proposed Transaction when they become available.

Disclaimer

Any information concerning eBay contained in this communication has been taken from, or based upon, publicly available information. Although GameStop does not have any information that would indicate that any information contained in this communication that has been taken from such documents is inaccurate or incomplete, GameStop does not take any responsibility for the accuracy or completeness of such information. To date, GameStop has not had access to the books and records of eBay.

Cautionary Statement Regarding Forward-Looking Statements – Safe Harbor

Certain statements in this communication may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “estimate,” “expect,” “predict,” “project,” “future,” “potential,” “intend,” “plan,” “assume,” “believe,” “forecast,” “look,” “build,” “focus,” “create,” “work,” “continue” or the negative of such terms or other variations thereof and words and terms of similar substance. Such statements also include, among others, statements with respect to GameStop’s proposed acquisition of eBay, such as statements about whether or not the transaction will occur, expected cost reductions, operational benefits, financing, the timing and structure of the transaction, anticipated benefits of the combination, leadership of the combined company, and similar statements. These forward-looking statements are based on GameStop’s current beliefs, expectations and assumptions and involve significant known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to: the failure of eBay’s Board of Directors to engage with the proposal; the failure to negotiate or execute a definitive agreement providing for the consummation of a transaction on the terms described or at all; failure to obtain required financing on the expected terms; failure to obtain required regulatory approvals; failure to obtain required shareholder approvals of GameStop and/or eBay; failure to realize anticipated cost reductions, operational benefits, or operating efficiencies; risks related to integration of the businesses; the impact of the announcement of the proposal on GameStop’s and eBay’s respective businesses, customers, suppliers, and employees; the diversion of management attention; competitive responses; market and economic conditions; and other risks described from time to time in GameStop’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended January 31, 2026 and subsequent filings. GameStop undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Final terms and conditions of any transaction are subject to negotiation and execution of a definitive agreement providing for the consummation of a transaction.

More News From GameStop Corp.

AMC Entertainment's stock price has staged a strong bull run this month, reaching its highest point since November last year.

It has jumped by 165% from its lowest point this year, and is about to form a golden cross pattern, which may hint at stronger gains ahead.

Technicals suggest that the AMC share price has more room to run, especially if the golden cross pattern forms.

The daily chart shows that the spread between the 50-day and 200-day Exponential Moving Averages (EMA) has narrowed substantially, and the crossover may happen as the momentum continues.

The 50-day EMA stands at $1.70, while the 200-day is at $1.96. 

Other technical indicators point to more gains this year. For example, the Average Directional Index (ADX) has jumped to 41, its highest point since May 1 this year. It has also jumped above the key resistance level of $1.93, its highest point on April 17. 

Therefore, the most likely AMC stock forecast is bullish, with the next level to watch being at $3.15, its highest level in October last year. A drop below the key support level of $1.93 will invalidate the bullish view.

AMC stock chart | Source: TradingView

The main reason behind the ongoing AMC stock rally is the ongoing rebound of the Box Office.

In a statement released earlier this month, the company said that it welcomed more than 4.2 million moviegoers to its US locations in May. 

Globally, the figure jumped to 25.5 million, the highest level since May 2019. This growth is a continuation of what has been happening this year, with titles like The Super Mario Galaxy, Michael, Project Hail Mary, The Devil Wears Prada 2, and Pegasus being among the most popular.

This growth will likely continue as several titles are expected to be released. This includes popular names like The Odyssey, Spider-Man: Brand New Day, Moana, and The Hunger Games.

AMC stock also rose after the company published its financial results. Its revenue rose to $1.04 billion in the first quarter from the $862 million it made last year. 

Its adjusted EBITDA improved to $38.3 million from a loss of $57.2 million in the same quarter last year. Also, it narrowed its losses, with its net loss improving to $117.1 million from the previous $201 million. 

Analysts are largely optimistic about the company, with the annual revenue expected to jump by 12% this year to $5.4 billion.

It is expected to jump to $5.7 billion next year, with the company expected to turn a net profit in 2027.

This view likely explains why the CEO recently bought shares worth over $344k. 

Still, the company has a major risk ahead: dilution. It recently completed its at-the-market raising of $150 million to boost its balance sheet.

Over time, AMC has boosted its outstanding shares from 58 million in 2023 to 605 million today. 

Today's Change

(

-24.64

%) $

-0.68

Current Price

$

2.08

AMC Entertainment Holdings (AMC 24.64%), a movie theater exhibition and cinema operator, closed at $2.83 and rose 6.39%. Traders were weighing record May attendance, a $150 million equity sale, and a $4 billion long-term debt load. Investors are watching summer box-office trends and the next earnings window for liquidity updates.
Trading volume reached 80.8 million shares, coming in about 140% above its three-month average of 33.6 million shares. AMC Entertainment Holdings IPO'd in 2013 and has fallen 99% since going public.

How the markets moved todayThe S&P 500 (^GSPC 1.44%) closed at 7,501 and rose 1.08%, while the Nasdaq Composite (^IXIC 2.21%) closed at 26,518 and gained 1.91%. Among movie theater and cinema operations peers, Cinemark Holdings (CNK +0.59%) closed at $33.76, up 1.96%, while National CineMedia (NCMI +3.57%) closed at $3.40, falling 6.34%.

What this means for investorsThe summer movie season is just kicking off, but AMC is already seeing solid attendance. The company said May saw the highest attendance since 2019, both domestically and globally. That has investors jumping into the theater operator’s stock.

The company still isn’t on solid financial footing, though. Investors need to consider more than just its debt load, too. Last week, AMC completed a $150 million equity offering to help boost its balance sheet.

That move helps the company, but it is dilutive to existing shareholders. AMC will likely need more than a single year of strong box-office attendance to reward shareholders.

Howard Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

AMC Entertainment (AMC - Free Report) ended the recent trading session at $2.74, demonstrating a -3.04% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.37%. Elsewhere, the Dow saw an upswing of 0.29%, while the tech-heavy Nasdaq depreciated by 1.33%.

The stock of movie theater operator has risen by 87.42% in the past month, leading the Consumer Discretionary sector's gain of 1.15% and the S&P 500's gain of 2.02%.

The upcoming earnings release of AMC Entertainment will be of great interest to investors. Meanwhile, our latest consensus estimate is calling for revenue of $1.45 billion, up 3.73% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.23 per share and revenue of $5.39 billion, which would represent changes of +76.04% and +11.1%, respectively, from the prior year.

It's also important for investors to be aware of any recent modifications to analyst estimates for AMC Entertainment. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 9.88% higher. AMC Entertainment is holding a Zacks Rank of #3 (Hold) right now.

The Leisure and Recreation Services industry is part of the Consumer Discretionary sector. Currently, this industry holds a Zacks Industry Rank of 188, positioning it in the bottom 23% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

AMC Entertainment Holdings shares fell sharply on Tuesday after the cinema operator announced a $200 million registered direct offering of common stock, triggering investor concerns over dilution.

The stock dropped 27% in trading as markets reacted to the issuance of more than 95 million new shares to institutional investors.

The move comes at a price of $2.10 per share, according to the company, and is expected to close on June 24, 2026, subject to customary closing conditions.

Net proceeds from the offering are expected to be approximately $189 million after fees and expenses, with Roth Capital Partners acting as the sole placement agent.

AMC said the majority of proceeds will be used to reduce debt, including the redemption of its $125.5 million in 6.125% Senior Subordinated Notes due 2027, along with associated costs.

Any remaining funds will be directed toward general corporate purposes, which may include additional debt repayment, liquidity support, and theatre upgrades.

The sharp decline in AMC shares reflected investor focus on dilution from the issuance of more than 95 million new shares.

The increase in outstanding shares is expected to reduce existing shareholders’ ownership percentage and dilute future earnings per share.

While the transaction improves liquidity and supports balance sheet repair, market reaction indicated that investors were more concerned about equity dilution than debt reduction benefits.

The stock had been on a strong run earlier in the year, rising 77% between Jan. 1 and Monday’s close, making the timing of the capital raise a key factor in the negative sentiment shift.

Debt reduction remains central to AMC strategyAMC has continued to prioritize strengthening its financial position after several years of pressure on the cinema industry.

The latest offering is part of that broader effort, with proceeds primarily earmarked for debt reduction.

Management also indicated that remaining funds may be used for additional debt repayment, liquidity reserves, or investments in theatre upgrades and customer experience initiatives across its cinema network.

The market response was intensified by the stock’s recent performance.

AMC shares had been trading at elevated levels in 2026, supported by strong box office trends and investor optimism around theatrical releases.

Earlier in the month, momentum was reinforced by a record-breaking opening weekend for Toy Story 5, which drew more than 4.8 million moviegoers to AMC and ODEON locations globally, marking the busiest US weekend of the year for the chain.

However, analysts had already warned that much of the bullish box office narrative was reflected in the share price.

The latest equity issuance added to concerns about repeated share sales, particularly following a prior $150 million at-the-market offering completed just days earlier involving more than 105 million shares.

Despite ongoing improvements in domestic box office performance and potential tailwinds from release schedules and industry developments, sentiment around AMC remains closely tied to its financing decisions and capital structure management.

Key Takeaways BlackBerry upgraded its UEM platform to support evolving enterprise and government security needs.New updates add stronger policy controls, malware detection and simpler profile administration.BlackBerry aims to compete in sovereign IT, cybersecurity and zero-trust adoption markets. As organizations worldwide face increasing cybersecurity threats, stricter data sovereignty regulations and the growing complexity of managing diverse device ecosystems, endpoint management has become a strategic priority. Against this backdrop, BlackBerry Limited’s (BB - Free Report) Secure Communications division recently upgraded its Unified Endpoint Management (UEM) platform, aimed at addressing the evolving needs of enterprises, governments and highly regulated industries.

UEM solutions have become crucial because they enable IT teams to manage multiple device types from a single console, enforce security policies consistently, protect sensitive corporate data, support BYOD and remote work initiatives, and ensure compliance with regulations. BlackBerry UEM addresses these needs through a centralized management framework that supports iOS, Android, Windows, ChromeOS and other enterprise platforms. The platform integrates mobile device management, mobile application management, secure communications, identity management and compliance monitoring.

BlackBerry continues to enhance UEM through recent updates, adding improved policy management, expanded controls for Android and iOS, better malware detection, simplified profile administration and stronger infrastructure support. These updates make the platform easier to deploy and manage, while also enhancing security visibility. Increasing geopolitical tensions and concerns about cyber warfare have prompted governments to modernize their secure communications infrastructure.

The endpoint management market continues to expand as organizations manage increasingly diverse device fleets and face mounting cybersecurity challenges. BlackBerry’s enhancements position the company to compete more effectively in several high-growth segments, such as sovereign IT infrastructure, government cybersecurity, enterprise mobility management, post-quantum security, managed security services and zero-trust architecture adoption. This differentiated positioning may allow BB to secure higher-value contracts and deepen relationships with existing customers.

How Does BB’s UEM Stack Up Against Cybersecurity Bigshots?CrowdStrike (CRWD - Free Report) remains leveraged to sustained cybersecurity demand as customers consolidate tools on the Falcon platform and expand module adoption through subscriptions and Falcon Flex. Rising cyber threats and data breaches continue to drive demand for cybersecurity solutions. It is well-positioned to benefit as enterprises prioritize modern defenses and vendor consolidation. Its Falcon platform spans endpoint, cloud, identity and data protection, helping customers reduce costs while strengthening security. With the cybersecurity market expected to witness a double-digit CAGR, CrowdStrike enjoys a favorable backdrop for continued market-share gains. CrowdStrike is expanding its customer base, driving revenue and creating long-term upsell opportunities within existing accounts.

Palo Alto Networks (PANW - Free Report) benefits from higher cybersecurity priority as enterprises deploy AI and look to consolidate vendors onto fewer platforms. Its platform benefits from a telemetry scale that processes more than 17 petabytes of daily telemetry, a data foundation that supports training, anomaly detection and faster outcomes. In May, PANW launched Idira, an identity security platform designed to manage and secure human, machine and AI agent identities across enterprises. Recently, PANW and Deutsche Telekom launched Sovereign Cortex with T Security, bringing the Cortex AI-driven SecOps platform to Europe’s highly regulated industries. The solution addresses growing cybersecurity and data sovereignty requirements.

BB Price Performance, Valuation & EstimatesShares of BlackBerry have surged 177.9% in the past three months compared with the Internet-Software industry’s growth of 2.7%.

Image Source: Zacks Investment Research

Regarding the price/book ratio, BB is trading at 7.2, higher than the industry’s multiple of 4.5.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for BB earnings for fiscal 2027 has been unchanged over the past 60 days.

Image Source: Zacks Investment Research

BlackBerry currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

BlackBerry Limited is rated a Hold ahead of its fiscal Q1 2027 report, with prior share gains driven by optimism in QNX and GEM segments. QNX and Secure Communications are key growth drivers, with QNX growing 14% and a $950 million backlog supporting future revenue. Cost restructuring, including the Cylance divestiture, removed a $150 million run rate, enabling eight consecutive quarters of improving GAAP net income.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +24% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Amgen (AMGN - Free Report) Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology, general medicine, inflammation and rare diseases markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta.  Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition. Amgen’s key products are Prolia, Xgeva, Repatha, Blincyto, Vectibix, Nplate, Kyprolis, Evenity, Otezla, Aimovig, Lumakras/Lumykras, Tezspire, Imdelltra, Tavneos, Kanjinti, Mvasi and Amgevita biosimilars. However, key drugs, Prolia and Xgeva, lost patent exclusivity in 2026. Multiple biosimilars have been launched globally.

AMGN is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

Momentum investors should take note of this Medical stock. AMGN has a Momentum Style Score of A, and shares are up 5.2% over the past four weeks.

Nine analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.04 to $22.22 per share. AMGN boasts an average earnings surprise of +11.8%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, AMGN should be on investors' short list.

Amgen (AMGN - Free Report) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Shares of this world's largest biotech drugmaker have returned +0.1% over the past month versus the Zacks S&P 500 composite's +1.4% change. The Zacks Medical - Biomedical and Genetics industry, to which Amgen belongs, has gained 1.9% over this period. Now the key question is: Where could the stock be headed in the near term?

While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.

Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.

Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.

For the current quarter, Amgen is expected to post earnings of $5.55 per share, indicating a change of -7.8% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.

For the current fiscal year, the consensus earnings estimate of $22.26 points to a change of +1.9% from the prior year. Over the last 30 days, this estimate has remained unchanged.

For the next fiscal year, the consensus earnings estimate of $23.7 indicates a change of +6.5% from what Amgen is expected to report a year ago. Over the past month, the estimate has remained unchanged.

With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Amgen.

The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:

12 Month EPS

Projected Revenue GrowthEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.

In the case of Amgen, the consensus sales estimate of $9.44 billion for the current quarter points to a year-over-year change of +2.9%. The $37.82 billion and $38.7 billion estimates for the current and next fiscal years indicate changes of +2.9% and +2.3%, respectively.

Last Reported Results and Surprise HistoryAmgen reported revenues of $8.62 billion in the last reported quarter, representing a year-over-year change of +5.8%. EPS of $5.15 for the same period compares with $4.9 a year ago.

Compared to the Zacks Consensus Estimate of $8.47 billion, the reported revenues represent a surprise of +1.71%. The EPS surprise was +8.88%.

The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.

ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.

Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.

As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.

Amgen is graded C on this front, indicating that it is trading at par with its peers. Click here to see the values of some of the valuation metrics that have driven this grade.

Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Amgen. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term.

Key Takeaways Amgen's biosimilar portfolio generated $835 million in Q1 2026 sales, up 14% year over year.New launches like Wezlana and Pavblu are helping offset declines in older biosimilar products.AMGN is advancing biosimilars to Opdivo, Keytruda and Ocrevus to tap major biologic markets. Historically known for its innovative biologic medicines such as Enbrel, Prolia and Repatha, Amgen (AMGN - Free Report) has also emerged as one of the global leaders in biosimilars. The company boasts a strong biosimilars portfolio and the business has become an increasingly important contributor to the company's top-line growth strategy. Its biosimilar portfolio spans oncology, inflammation and rare diseases.

Some of Amgen's older biosimilars — Kanjinti (a biosimilar of Roche’s [(RHHBY - Free Report) ] Herceptin), Mvasi (a biosimilar of Roche’s Avastin), Riabni (a biosimilar to Roche’s Rituxan), Avsola (a biosimilar to J&J’s [(JNJ - Free Report) ] Remicade) and Amjevita/Amgevita (a biosimilar of AbbVie’s Humira) — are seeing slowing/declining sales due to rising competitive pressure.

To combat the impact, Amgen has successfully launched biosimilars of J&J’s Stelara, called Wezlana, AstraZeneca’s (AZN - Free Report) Soliris, called Bekemv, and Regeneron’s Eylea, called Pavblu, in the past couple of years.

In the first quarter of 2026, its biosimilar products generated sales of $835 million, up 14% year over year, including $47 million from Wezlana and $280 million from Pavblu. Since the first launch in 2018, Amgen’s biosimilar drugs have delivered more than $14 billion in sales, significantly contributing to top-line growth and generating meaningful cash flows.

Amgen is also developing biosimilars referencing some of the pharmaceutical industry's largest biologics. Phase III studies are ongoing to evaluate biosimilar versions of Bristol-Myers’ Opdivo (ABP 206), Merck’s Keytruda (ABP 234) and Roche’s Ocrevus (ABP 692). These medicines collectively generate tens of billions of dollars in annual sales globally. As patents on these products expire over the next several years, biosimilars targeting them could create substantial revenue opportunities for Amgen.

Over the next few years, Amgen will face a significant patent-expiration overhang. Its own key branded products, such as Prolia, Xgeva, Enbrel and Otezla, have either already lost exclusivity or are expected to do so within the next few years. Together, these medicines accounted for roughly 30% of Amgen’s 2025 product sales, leaving the company exposed to potential revenue pressure from generic and biosimilar competition as patents expire.

Amgen’s new biosimilar launches will play a key role in mitigating the impact of LOE over the next few years, along with Amgen’s key growth drivers, which include Repatha, Evenity, Tezspire and some oncology and rare disease drugs.

While Amgen's biosimilars may not individually achieve blockbuster status comparable to leading innovative therapies, together they represent a meaningful source of recurring revenues, enhance portfolio diversification and provide access to some of the world's largest biologic markets. Over the long term, the biosimilars business is expected to remain a key pillar of Amgen's strategy, supporting a more diversified, resilient and sustainable growth profile.

AMGN’s Price Performance, Valuation and EstimatesAmgen’s stock has risen 5.3% so far this year compared with an increase of 1.3% for the industry.

Image Source: Zacks Investment Research

From a valuation standpoint, Amgen is reasonably priced. Going by the price/earnings ratio, the company’s shares currently trade at 15.02 forward earnings, which is lower than 17.05 for the industry. The stock is also trading above its five-year mean of 13.81.

Image Source: Zacks Investment Research

The Zacks Consensus Estimate for earnings has risen from $22.21 per share to $22.26 per share for 2026 over the past 60 days. For 2027, the consensus mark for earnings has risen from $23.35 to $23.70 per share over the same timeframe.

Image Source: Zacks Investment Research

Amgen has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

PALO ALTO, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Upwork Inc. (NASDAQ: UPWK), the world's human and AI-powered work marketplace, today announced the Upwork Claude Connector, a new app inside Anthropic's Claude that connects businesses with the experts they need the moment a project takes shape.

According to recent Upwork research, 74% of SMBs plan to increase freelancer hiring in the near term, much of it tied to AI-driven growth initiatives. Now the same tools that support the project planning can also help with the hiring, without starting from scratch or losing the context that’s already been built.

“AI is changing how businesses plan and kick off work. But quality outcomes still depend on human expertise,” said Peter Sanborn, chief business officer at Upwork Inc. “Putting Upwork inside Claude closes the gap between where work gets started and the talent that can bring it to life.”

With the Upwork Claude Connector, a user can describe a project and immediately receive a shortlist of recommended talent drawn from the Upwork Marketplace’s more than 18 million professionals, including a global pool of AI-skilled talent, across 130 categories of work. They can also create a job post through the conversation, then continue to Upwork to make the hire — where Uma™, Upwork's AI work agent, helps manage the project to completion.

Claude users can get started with prompts like:

“Start an Upwork job post for a data analyst who can build an AI system that turns our raw customer support transcripts into weekly trend reports.”“Our finance team spends hours on manual reporting every month. Can you help me find an AI automation expert on Upwork who can build a solution to fix that?”“I've drafted this product spec in Claude. Find me a senior engineer who's shipped similar features and can build it.” When Shane Pope, CEO of Reflect Technology, set out to build Remi, an AI-powered mental wellness app, he turned to Upwork to find the AI expertise he needed. The app went from idea to the App Store in four months. “Sometimes you're working through a business problem and you realize you need an expert — and a real person would be 10 times more helpful than AI alone,” said Shane. “Being able to find that person on Upwork right there in the same conversation, without the back-and-forth, just removes the friction that makes you put it off.”

The Claude integration follows the launch of an Upwork app for ChatGPT in April, and is part of Upwork’s growing effort to expand access to expert talent inside the tools where ideas take shape.

All Claude users can get started now by connecting the Upwork app within Claude. Learn more at: upwork.com/claudeapp-support.

About Upwork
Upwork Inc.’s (Nasdaq: UPWK) family of companies connects businesses with global, AI-enabled talent across every contingent worker classification. This portfolio includes the Upwork Marketplace, which connects businesses with on-demand access to highly skilled talent across the globe, and Lifted, which provides a purpose-built solution for enterprise organizations to source, contract, manage, and pay talent across the full spectrum of contingent work. From Fortune 100 enterprises to entrepreneurs, businesses rely on Upwork Inc. to find and hire expert talent, leverage AI-powered work solutions, and drive business transformation. With access to professionals spanning more than 10,000 skills across AI & machine learning, software development, sales & marketing, customer support, finance & accounting, and more, the Upwork family of companies enables businesses of all sizes to scale, innovate, and transform their workforces for the age of AI and beyond.

Since its founding, Upwork Inc. has facilitated more than $30 billion in total transactions and services as it fulfills its purpose to create opportunity in every era of work. Learn more about the Upwork Marketplace at upwork.com and follow on LinkedIn, Facebook, Instagram, TikTok, and X; learn more about Lifted at go-lifted.com and follow on LinkedIn.

Contact:
Elisabeth Hutchinson
[email protected]

NEW YORK, June 19, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Zillow Group, Inc. (NASDAQ:Z, ZG) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.

Lead Plaintiff Deadline: August 10, 2026Alleged Misconduct: Securities fraud relating to Zillow’s allegedly anticompetitive agreement with Redfin CorporationLargest Alleged Stock Drop: February 11, 2026 – 16.54% Stock Drop on Class C shares; 17.13% Stock Drop on Class A shares.Court: U.S. District Court for the Western District of WashingtonAction: Contact BFA Law to discuss your rights Investors have until August 10, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Zillow Class C and Class A common stock. The class action is pending in the U.S. District Court for the Western District of Washington. It is captioned Breidert v. Zillow Group, Inc., et al., No. 26-cv-02016.

Why is Zillow Being Sued for Securities Fraud?

On February 6, 2025, Zillow entered into an agreement with Redfin through which Zillow became the exclusive provider of multifamily rental listings on Redfin’s platform and affiliate websites, including Rent.com. According to the complaint, during the relevant period, Zillow characterized the agreement with Redfin as a “partnership” that would provide Zillow exclusive access to Redfin’s advertising platform.

As alleged, in truth, under the terms of the agreement, Zillow paid Redfin $100 million to stop competing with Zillow, facilitate the transition of its multifamily rental advertising business to Zillow, and close the remainder of its business.

Why did Zillow’s Stock Drop?

On September 30, 2025, the FTC filed a complaint against Zillow and Redfin alleging violations of the federal antitrust laws. According to the FTC complaint, “Zillow and Redfin executed an unlawful agreement to remove competition from [the online rental marketplaces industry], starting with a $100 million payment to Redfin to exit the [Internet Listing Services] market.” In sum, the FTC alleged, “[t]his agreement is nothing more than an end run around competition on the merits with Redfin for customers…” This news caused the price of Zillow’s Class C and A common stock to decline 4.33% and 4.5%, respectively.

On February 10, 2026, Zillow’s CFO told investors that Zillow experienced increased legal expenses which “will result in approximately 200 basis points headwind to EBITDA margins in Q1.” On this news, the price of Zillow’s Class C and A common stock declined 16.54%, and 17.13%, respectively.

Finally, on May 7, 2026, Reuters reported that a “federal judge rejected [Zillow and Redfin’s] request to end a [FTC] lawsuit accusing them of illegally agreeing to suppress competition for online apartment rental listings.” This news caused the price of Zillow’s Class C and A common stock to decline 1.9% and 1.76%, respectively.   

Click here for more information: https://www.bfalaw.com/cases/zillow-class-action-lawsuit.

What Can You Do?

If you invested in Zillow, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/zillow-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.” 

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/zillow-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

New York, New York--(Newsfile Corp. - June 19, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Zillow common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302188

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, June 20, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Zillow common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Zillow’s agreement with Redfin Corporation was not a “partnership,” but rather an acquisition of Redfin’s business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants’ statements about Zillow’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

So what: If you purchased Zillow common stock during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/z-zg-investors-have-opportunity-to-lead-zillow-group-inc-securities-fraud-lawsuit-filed-by-the-rosen-law-firm-302805472.html

SOURCE THE ROSEN LAW FIRM, P. A.

New York, New York--(Newsfile Corp. - June 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Class A or Class C common stock of Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) between February 11, 2025 and May 7, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

SO WHAT: If you purchased Zillow common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 10, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Zillow's agreement with Redfin Corporation was not a "partnership," but rather an acquisition of Redfin's business; (2) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (3) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (4) as a result, defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Zillow class action, go to https://rosenlegal.com/cases/zillow-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302199

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Zillow Group, Inc. (NASDAQ:Z, ZG) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws.

Lead Plaintiff Deadline: August 10, 2026Alleged Misconduct: Securities fraud relating to Zillow’s allegedly anticompetitive agreement with Redfin CorporationLargest Alleged Stock Drop: February 11, 2026 – 16.54% Stock Drop on Class C shares; 17.13% Stock Drop on Class A shares.Court: U.S. District Court for the Western District of WashingtonAction: Contact BFA Law to discuss your rights
Investors have until August 10, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Zillow Class C and Class A common stock. The class action is pending in the U.S. District Court for the Western District of Washington. It is captioned Breidert v. Zillow Group, Inc., et al., No. 26-cv-02016.

Why is Zillow Being Sued for Securities Fraud?

On February 6, 2025, Zillow entered into an agreement with Redfin through which Zillow became the exclusive provider of multifamily rental listings on Redfin’s platform and affiliate websites, including Rent.com. According to the complaint, during the relevant period, Zillow characterized the agreement with Redfin as a “partnership” that would provide Zillow exclusive access to Redfin’s advertising platform.

As alleged, in truth, under the terms of the agreement, Zillow paid Redfin $100 million to stop competing with Zillow, facilitate the transition of its multifamily rental advertising business to Zillow, and close the remainder of its business.

Why did Zillow’s Stock Drop?

On September 30, 2025, the FTC filed a complaint against Zillow and Redfin alleging violations of the federal antitrust laws. According to the FTC complaint, “Zillow and Redfin executed an unlawful agreement to remove competition from [the online rental marketplaces industry], starting with a $100 million payment to Redfin to exit the [Internet Listing Services] market.” In sum, the FTC alleged, “[t]his agreement is nothing more than an end run around competition on the merits with Redfin for customers…” This news caused the price of Zillow’s Class C and A common stock to decline 4.33% and 4.5%, respectively.

On February 10, 2026, Zillow’s CFO told investors that Zillow experienced increased legal expenses which “will result in approximately 200 basis points headwind to EBITDA margins in Q1.” On this news, the price of Zillow’s Class C and A common stock declined 16.54%, and 17.13%, respectively.

Finally, on May 7, 2026, Reuters reported that a “federal judge rejected [Zillow and Redfin’s] request to end a [FTC] lawsuit accusing them of illegally agreeing to suppress competition for online apartment rental listings.” This news caused the price of Zillow’s Class C and A common stock to decline 1.9% and 1.76%, respectively.   

Click here for more information: https://www.bfalaw.com/cases/zillow-class-action-lawsuit.

What Can You Do?

If you invested in Zillow, you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/zillow-class-action-lawsuit

Or contact:
Adam McCall
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters.

Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.” 

Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/zillow-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 22, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) ("Zillow" or the "Company"), if they purchased or otherwise acquired Zillow Class A or Class C common stock between February 11, 2025 and May 7, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Washington.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=hIyQUNEoCGc

What You May Do

If you purchased shares of Zillow as described above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-zg-z/?prs=nf to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 10, 2026.

CLICK HERE for more information

About the Lawsuit

Zillow and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

The alleged false and misleading statements and omissions include, but are not limited to, that: (i) Zillow's agreement with Redfin was not a "partnership," but rather an acquisition of Redfin's business; (ii) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (iii) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (iv) as a result, Defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

The case is Breidert v. Zillow Group, Inc., et al., 26-cv-02016.

To Learn More, Click HERE

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors, in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

For More Information about the case, Click HERE

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/302415

Source: Kahn Swick & Foti, LLC

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us